Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
04/02/2008 08:54
PR Newswire
BASEL, Switzerland, February 4 /PRNewswire/ -- Synosia Therapeutics today announced the appointment of
Philippe Lutz MA Finance, as the company's first chief financial officer,
effective immediately. He will be based at Synosia's new headquarters in
Basel, Switzerland.
Lutz joins Synosia from Credit Suisse Investment Banking where
he most recently served as a vice president of the global markets solutions
group. In a nine-year career at Credit Suisse, he contributed to a broad
range of capital market transactions and successfully completed the chartered
financial analyst exams (CFA). Lutz is a Swiss national and earned his
masters in business administration from the University of St. Gallen.
"Since Synosia started operations just over two years ago,
we've established partnerships with Roche, Novartis and Syngenta, designed
and completed our first clinical trial, prepared to start four phase II
trials later this year, and built strong teams in both San Francisco and
Basel," said the company's Chief Executive Officer and President Ian Massey.
"The establishment of our corporate headquarters in
Switzerland and the appointment of Philippe Lutz is a further step in our
progression to a mature development organization; it also underscores the
importance of Switzerland as a centre of excellence for the management,
clinical development and extension of our portfolio of compounds," Dr Massey
continued.
"I knew that Synosia was the company I wanted to join once I
met the management team and saw the extraordinary progress the company has
made," said Lutz. "I was also pleased to learn of the new headquarters in
Switzerland. The strength of Switzerland's pharmaceutical sector should help
sustain Synosia's ambitious development programme."
About Synosia Therapeutics
Synosia Therapeutics develops and intends to commercialize
innovative and clinically differentiated products for unmet medical needs in
psychiatry and neurology. The privately-owned company is developing six
clinical-stage compounds acquired through key partnerships with Novartis,
Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will
be tested in new indications, extending their reach into new neurological and
psychiatric diseases with high unmet medical need, including anxiety and
Parkinson's Disease. Synosia's corporate headquarters is in Basel,
Switzerland.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning Synosia Therapeutics and its business.
Such statements involve certain known and unknown risks, uncertainties and
other factors which could cause the actual results, financial condition,
performance or achievements of Synosia Therapeutics to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements.
Synosia Therapeutics is providing this communication as of
this date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or otherwise.
Contact:
Synosia Therapeutics
In Europe:
Julie Walters at Tudor Reilly
Tel: +44(0)20-7016-7714
Mobile +44(0)775-3626967
julie.walters@tudor-reilly.com
In US:
Michele Parisi at Tudor Reilly
Tel: +1-925-864-5028
michele.parisi@tudor-reilly.com
Synosia Therapeutics, In Europe: Julie Walters at Tudor Reilly, Tel: +44(0)20-7016-7714, Mobile +44(0)775-3626967, julie.walters@tudor-reilly.com; In US: Michele Parisi at Tudor Reilly, Tel: +1-925-864-5028, michele.parisi@tudor-reilly.com